Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Apr. 30, 2018
Apr. 30, 2017
Apr. 30, 2018
Apr. 30, 2017
Revenues:        
Revenues $ 25,630 $ 27,089 $ 80,258 $ 79,633
Operating costs and expenses:        
Research and development 799 766 2,358 2,071
Selling, general and administrative 11,025 10,534 32,986 33,246
Provision for uncollectible accounts receivable 396 620 1,989 1,968
Legal fee expense 1,651 512 3,782 1,254
Total operating costs and expenses 28,428 27,348 86,710 82,232
Operating loss (2,798) (259) (6,452) (2,599)
Other income (expense):        
Interest 227 115 569 240
Other 17 (74) 86 69
Foreign exchange gain (loss) (462) 147 143 (308)
Loss before income taxes (3,016) (71) (5,654) (2,598)
Benefit for income taxes   0 1,097 0
Net loss $ (3,016) $ (71) $ (4,557) $ (2,598)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.06) $ 0.00 $ (0.10) $ (0.06)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 47,073 46,367 46,895 46,310
Clinical Laboratory Services [Member]        
Revenues:        
Revenues $ 18,137 $ 19,584 $ 58,001 $ 56,979
Operating costs and expenses:        
Cost of Revenues 10,995 11,334 34,767 33,282
Product [Member]        
Revenues:        
Revenues 7,415 7,312 21,618 21,721
Operating costs and expenses:        
Cost of Revenues 3,562 3,582 10,828 10,411
Royalty and License Fees [Member]        
Revenues:        
Revenues $ 78 $ 193 $ 639 $ 933